Study Summary
This trial is testing a combination of antibodies and T cells to treat lung cancer. It will look at how much of the treatment is safe and what dosage is the most effective.
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
- Lung Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
3 Primary · 8 Secondary · Reporting Duration: Up to 2 years
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
iC9.GD2.CAR.IL-15 T Therapy
1 of 1
Experimental Treatment
24 Total Participants · 1 Treatment Group
Primary Treatment: iC9.GD2.CAR.IL-15 T Therapy · No Placebo Group · Phase < 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What state do they live in?
| Maryland | 100.0% |
What portion of applicants met pre-screening criteria?
| Did not meet criteria | 100.0% |
How many prior treatments have patients received?
| 3+ | 100.0% |
Frequently Asked Questions
What is the fundamental aim of this clinical study?
"This medical trial is assessing cytokine release syndrome (CRS) for a time frame of up to 4 weeks. Secondary outcomes in this study include disialoganglioside expression, overall response rate and duration of response which will be measured using immunohistochemistry on tumor samples collected from participants according to Response Evaluation Criteria In Solid Tumors criteria. ORR is calculated by summing the number of patients that achieved complete or partial responses divided by the total number who received treatment while DOR is noted as starting with either partial or full respose to disease progression based on RECIST 1.1 metrics: CR defined as disappearance" - Anonymous Online Contributor
Are patients being recruited for this experiment currently?
"According to clinicaltrials.gov, this medical experiment is no longer enrolling candidates. It was initially listed on January 15th 2023 and its most recent update occurred in November 16th 2022. Nevertheless, 1979 other trials are actively recruiting patients at the present time." - Anonymous Online Contributor